Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

British journal of pharmacology - 1 Nov 2008

McPate M J, Duncan R S, Hancox J C, Witchel H J

Abstract excerpt

BACKGROUND AND PURPOSE: The short QT syndrome (SQTS) is associated with cardiac arrhythmias and sudden death. The SQT1 form of SQTS results from an inactivation-attenuated, gain-of-function mutation (N588K) to the human ether-à-go-go-related gene (hERG) potassium channel. Pharmacological blockade of this mutated hERG channel may have therapeutic value. However, hERG-blocking potencies of canonical inhibitors such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Arrhythmias, Cardiac

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CHO Cells

Share to Cricetinae

Share to Cricetulus

Share to Electrophysiology

Share to Ether-A-Go-Go Potassium Channels

Share to Patch-Clamp Techniques

Source

Open in PubMed Open full text

Identifiers

PMID: 18724381
DOI: 10.1038/bjp.2008.325
PMCID: PMC2597231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.PMID 18724381Read ↗

Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.Semantic proximity Read ↗

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.Semantic proximity Read ↗

Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.Semantic proximity Read ↗

Emerging therapeutic targets in the short QT syndrome.Semantic proximity Read ↗

Molecular Basis for state-dependent drug block of Kv11.1 (HERG) potassium channelsSemantic proximity Read ↗

Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.Semantic proximity Read ↗

Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction.Semantic proximity Read ↗

Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.Semantic proximity Read ↗

A novel mutation in the KCNH2 gene associated with short QT syndrome.Semantic proximity Read ↗

Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels.Semantic proximity Read ↗

The hERG K(+) channel S4 domain L532P mutation: characterization at 37°C.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.